시장보고서
상품코드
1826958

세계의 신경근 질환용 핵산 및 유전자 치료 시장 보고서(2025년)

Nucleic Acid And Gene Therapies In Neuromuscular Disorders Global Market Report 2025

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 250 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

신경근 질환용 핵산 및 유전자 치료 시장 규모는 최근 몇 년 동안 강력하게 성장하고 있습니다. 2024년 68억 4,000만 달러, 2025년에는 75억 달러에 달하고, CAGR 9.6%로 성장할 전망입니다. 역사적인 기간의 성장은 규제 당국의 승인 증가, 핵산 치료제에 대한 수요, 보다 정밀하고 효과적인 치료에 대한 수요, 효과적인 유전자 치료에 대한 수요, 유전자 치료에 기초한 발견 증가에 기인합니다.

신경근 질환용 핵산 및 유전자 치료 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 9.5%로 107억 8,000만 달러로 성장할 것으로 예상됩니다. 예측기간의 성장은 유전성 질환의 유병률 증가, 연구개발 투자 증가, 정밀의료 수요 증가, 유전자 치료제 승인률 증가, 만성질환 유병률 증가로 인한 것입니다. 예측 기간의 주요 동향으로는 환자 관리의 진보, 고성능 크로마토그래피, 병리학에 대한 혁신적인 솔루션, 유전자 편집 기술의 발전, 핵산 추출 기술의 가용성 등이 있습니다.

신경근 장애의 핵산 및 유전자 치료는 이러한 질병을 유발하는 유전자 변이를 수정하거나 보완하도록 설계된 혁신적인 치료법입니다. 신경근 질환(NMD)은 근육과 신경에 영향을 미치는 질병으로, 종종 유전성 돌연변이로 인해 발생합니다. 이러한 치료법은 핵산과 유전 물질을 이용하여 유전자 발현을 복구, 대체, 조절하고 장애의 근본 원인을 해결합니다.

이러한 치료가 대상으로 하는 주요 질환으로는 운동 뉴런 질환, 신경 장애, 신경근 접합부 장애, 근이영양증 등의 미오파티가 있습니다. 운동 뉴런 질환은 운동 뉴런에 영향을 미치고 근력 저하, 위축 및 선택적인 운동의 통제 불능을 일으키는 진행성 신경 질환 그룹입니다. 치료 접근법은 아데노 관련 바이러스(AAV) 유전자 치료, 출생 후 유전자 치료, 척수성 근위축증 치료 등을 포함합니다. 이러한 치료법은 병원, 전문 클리닉, 외래수술센터(ASC) 등 다양한 건강 관리 환경에서 적용됩니다.

2025년 봄 미국 관세의 급상승과 이에 따른 무역 마찰은 건강 관리 분야, 특히 필수적인 의료기기, 진단 장비 및 의약품 공급에 큰 영향을 미쳤습니다. 병원과 건강 관리 제공업체는 수입되는 수술 기구, 영상 진단 시스템, 주사기 및 카테터와 같은 소모품의 비용 상승에 시달리고 있으며, 그 대부분은 국내 대체품이 제한되어 있습니다. 이러한 비용 상승이 의료 예산을 압박하기 때문에 일부 의료기관은 장비 업그레이드를 늦추거나 비용 증가를 환자에게 전가하고 있습니다. 게다가 원료와 부품에 대한 관세는 중요한 의약품과 의료기기의 제조에 지장을 주고 공급망의 지연으로 이어지고 있습니다. 이에 비해 업계는 다양한 조달 전략을 채택하고 가능한 한 현지 생산을 확대하고 중요한 의료 제품의 관세 면제를 수행하고 있습니다.

이 조사 보고서는 신경근 질환용 핵산 및 유전자 치료 업계 세계 시장 규모, 지역 점유율, 신경근 질환용 핵산 및 유전자 치료 시장 점유율을 가진 경쟁 기업, 상세한 신경근 질환용 핵산 및 유전자 치료 시장 부문, 시장 동향과 비즈니스 기회, 신경근 질환용 핵산 및 유전자 치료 업계에서 성공하기 위해 필요한 데이터 등 신경근 질환용 핵산 및 유전자 치료 시장 통계를 제공합니다. 이 신경근 질환의 핵산 및 유전자 치료 시장 조사 보고서는 업계의 현재 및 미래 시나리오를 자세히 분석하고 필요한 모든 것을 완벽한 관점에서 제공합니다.

향후 5년간의 성장률 9.5%라고 하는 예측은 전회의 예측으로부터 0.2%의 소폭 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세 부과는 스위스나 한국에서 수입되는 아데노 관련 바이러스 벡터 기반의 치료제이나 클러스터드 레귤러 인터스페이시스 쇼트 패린드로믹 리피트(Cas9) 성분의 비용을 상승시키고, 전문 약국의 비용을 인상하고, 희귀질환의 치료를 연기할 수 있기 때문에 미국의 의료 기술 혁신 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

유전성 질환의 유병률 증가는 신경근 질환 시장에서 핵산 및 유전자 치료의 성장을 가속할 것으로 예측됩니다. 유전성 질환은 유전성 또는 돌연변이로 인한 개인의 DNA 이상으로 인한 것입니다. 이러한 질병 증가는 유전자 돌연변이, 환경 영향, 라이프 스타일 변화, 진단 기술의 발전 등의 요인 때문입니다. 핵산 및 유전자 치료는 정상적인 기능을 회복시키기 위해 결함이 있는 유전자를 수정하거나 대체함으로써 유전성 신경근 장애를 다루는데 중요한 역할을 합니다. 예를 들어 미국에 본사를 둔 비영리 단체 큐어 SMA에 따르면 2024년 5월 현재 미국에서는 약 9,000명에서 9,500명이 척수성 근위축증(SMA)을 앓고 있으며, 그 37%를 2형 SMA가 차지하고 있습니다. SMA의 예상 발병률은 출생 1만 5,000명 중 1명입니다. 그 결과, 유전성 질환의 유병률 증가가 신경근질환 시장에서의 핵산 및 유전자 치료 수요를 촉진하고 있습니다.

이 시장의 주요 기업은 유전적인 신경근 질환의 근본적인 원인을 유전자의 정확한 수정과 치환에 의해 직접 타겟팅하는 유전자 치료 솔루션을 진행하고 있습니다. 유전자 치료는 결함 유전자를 다루기 위해 환자의 세포에서 유전 물질을 수정하거나 복구하는 것을 포함합니다. 예를 들어, 2023년 6월 미국의 생명 공학 회사인 Sarepta Therapeutics Inc.는 4세에서 5세 사이의 외래 소아 환자를 대상으로 하는 Dushenne 근이영양증(DMD)에 대한 최초의 유전자 치료제인 Elevidys의 FDA 승인을 받았습니다. Elevidys는 한 번의 드립 정주로 투여되며 드립 정주 요법을 대체하는 간단한 치료법입니다. 이 치료법은 근육 기능에 중요한 마이크로 디스트로핀으로 알려진 디스트로핀의 단축형을 코딩하는 유전자를 투여하는 것입니다. 근세포가 기능적인 디스트로핀 단백질을 생산할 수 있게 함으로써, 엘레비디스는 질병의 진행을 늦추거나 역전시키는 것을 목표로 합니다.

2024년 11월 스위스 제약회사 노발티스 AG는 Kate Therapeutics사를 11억 달러로 인수했습니다. 이 인수는 유전성 신경근 질환에 대한 노바티스의 유전자 치료 포트폴리오를 강화하는 것을 목표로 합니다. 케이트 세라퓨틱스의 AAV 기반 유전자 치료 플랫폼 DELIVER와 듀첸느형 근이영양증, 안면 견갑상완 이영양증, 근강직성 이영양증 1형의 전임상 후보를 통합함으로써, 노바티스는 유전성 근질환과 심장질환의 표적 치료 개발 능력을 확대합니다. Kate Therapeutics Inc.는 미국을 기반으로 하는 생명공학 기업으로 유전적으로 정의된 신경근 질환에 대한 아데노 관련 바이러스(AAV) 기반 유전자 치료를 전문으로 하고 있습니다.

신경근 질환의 핵산 및 유전자 치료 시장은 유전자 진단, 개인화 치료, 유전자 도입 등의 서비스를 제공하는 기업이 얻는 수익으로 구성되어 있습니다. 시장 가치에는 서비스 제공업체가 판매하거나 서비스 제공에 포함된 관련 상품의 가치가 포함됩니다. 신경근 질환의 핵산 및 유전자 치료 시장에는 올리고뉴클레오티드, 유전자 치료 벡터 및 진단 키트의 판매도 포함됩니다. 이 시장의 가치는 "Factory Gate"가치, 즉 다른 기업(다운스트림 제조업자, 도매업체, 유통업체, 소매업체 포함)이든 직접 최종 고객이든, 상품 제조자 또는 제작자가 판매한 상품의 가치입니다. 이 시장에서 상품의 가치에는 상품 제작자에 의해 판매되는 관련 서비스도 포함됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

  • 세계의 신경근 질환용 핵산 및 유전자 치료 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
  • 최종 이용 산업의 분석
  • 세계의 신경근 질환용 핵산 및 유전자 치료 시장 : 성장률 분석
  • 세계의 신경근 질환용 핵산 및 유전자 치료 시장 실적 : 규모와 성장, 2019-2024
  • 세계의 신경근 질환용 핵산 및 유전자 치료 시장 예측 : 규모와 성장, 2024-2029, 2034F
  • 세계의 신경근 질환용 핵산 및 유전자 치료 : 전체 시장 규모(TAM)

제6장 시장 세분화

  • 세계의 신경근 질환용 핵산 및 유전자 치료 시장 : 장애에 의해 분석과 예측, 2019-2024, 2024-2029F, 2034F
  • 운동 신경 질환
  • 신경장애
  • 신경근 접합부 질환
  • 근이영양증을 포함한 근병증
  • 세계의 신경근 질환용 핵산 및 유전자 치료 시장 : 테라피별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
  • 아데노 관련 바이러스 유전자 치료
  • 출생 후 유전자 치료
  • 척수 근위축증
  • 세계의 신경근 질환용 핵산 및 유전자 치료 시장 : 용도별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
  • 병원
  • 전문 클리닉
  • 외래수술센터(ASC)
  • 세계의 신경근 질환용 핵산 및 유전자 치료 시장 : 세분화 운동 신경 질환(유형별), 분석과 예측, 2019-2024, 2024-2029F, 2034F
  • 근위축성 측삭 경화증(ALS)
  • 척수 근위축증(SMA)
  • 원발성 측삭 경화증(PLS)
  • 세계의 신경근 질환용 핵산 및 유전자 치료 시장 : 세분화 신경장애 유형별, 분석과 예측
  • 샤르코·마리·투스병(CMT)
  • 유전성 감각 자율 신경 장애(HSAN)
  • 말초신경장애
  • 세계의 신경근 질환용 핵산 및 유전자 치료 시장 : 세분화 신경근 접합부 질환(유형별), 분석과 예측
  • 중증근무력증
  • 램버트 이튼 근무력 증후군(LEMS)

제7장 지역별/국가별 분석

  • 세계의 신경근 질환용 핵산 및 유전자 치료 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
  • 세계의 신경근 질환용 핵산 및 유전자 치료 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

  • 신경근 질환용 핵산 및 유전자 치료 시장 : 경쟁 구도
  • 신경근 질환용 핵산 및 유전자 치료 시장 : 기업 프로파일
    • Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
    • F. Hoffmann-La Roche Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
    • Bayer AG : 개요, 제품 및 서비스, 전략 및 재무 분석
    • Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
    • Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

  • Eli Lilly and Company
  • Astellas Pharma Inc
  • Biogen Inc
  • Vertex Pharmaceuticals Inc
  • BioMarin Pharmaceuticals Inc
  • Nippon Shinyaku Co Ltd
  • Sarepta Therapeutics Inc
  • Ionis Pharmaceuticals, Inc.
  • Ultragenyx Pharmaceutical Inc
  • Amicus Therapeutics Inc
  • Arrowhead Pharmaceuticals Inc
  • Regenxbio Inc
  • UniQure NV
  • Genethon SA
  • Axovant Gene Therapies, Inc

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

  • 신경근 질환용 핵산 및 유전자 치료 시장 2029 : 새로운 기회를 제공하는 국가
  • 신경근 질환용 핵산 및 유전자 치료 시장 2029 : 새로운 기회를 제공하는 부문
  • 신경근 질환용 핵산 및 유전자 치료 시장 2029 : 성장 전략
    • 시장 동향에 기초한 전략
    • 경쟁 전략

제36장 부록

SHW 25.10.17

Nucleic acid and gene therapies for neuromuscular disorders are innovative treatments designed to correct or compensate for genetic mutations that cause these conditions. Neuromuscular disorders (NMDs) affect the muscles and nerves, often due to inherited mutations. These therapies utilize nucleic acids or genetic material to repair, replace, or modulate gene expression, addressing the underlying cause of the disorder.

The primary disorders targeted by these therapies include motor neuron diseases, neuropathies, neuromuscular junction disorders, and myopathies such as muscular dystrophies. Motor neuron diseases are a group of progressive neurological conditions that impact motor neurons, leading to muscle weakness, atrophy, and loss of voluntary movement control. Treatment approaches include adeno-associated virus (AAV) gene therapy, postnatal gene therapy, and therapies for spinal muscular atrophy. These therapies are applied in various healthcare settings, including hospitals, specialty clinics, and ambulatory surgery centers.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The nucleic acid and gene therapies in neuromuscular disorders market research report is one of a series of new reports from The Business Research Company that provides nucleic acid and gene therapies in neuromuscular disorders market statistics, including nucleic acid and gene therapies in neuromuscular disorders industry global market size, regional shares, competitors with a nucleic acid and gene therapies in neuromuscular disorders market share, detailed nucleic acid and gene therapies in neuromuscular disorders market segments, market trends and opportunities, and any further data you may need to thrive in the nucleic acid and gene therapies in neuromuscular disorders industry. This nucleic acid and gene therapies in neuromuscular disorders market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The nucleic acid and gene therapies in neuromuscular disorders market size has grown strongly in recent years. It will grow from $6.84 billion in 2024 to $7.5 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to increase in regulatory approvals, demand for nucleic acid therapeutics, demand for more precise and effective therapies, demand for effective gene therapies, and increase in the number of gene therapy-based discoveries.

The nucleic acid and gene therapies in neuromuscular disorders market size is expected to see strong growth in the next few years. It will grow to $10.78 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to increasing prevalence of genetic disorders, increasing investments in research and development, growing demand for precision medicine, rising approval of gene therapy products, and increasing prevalence of chronic disorders. Major trends in the forecast period include advances in patient care, high performance chromatography, innovative solutions for conditions, advancements in gene editing technologies, and availability of nucleic acid extraction technology.

The forecast of 9.5% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. medical innovation by increasing costs for Adeno-associated virus vector-based therapies and Clustered regularly interspaced short palindromic repeats -Cas9 components imported from Switzerland and South Korea, potentially raising specialty pharmacy costs and postponing rare disease treatments. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of genetic disorders is expected to drive the growth of the nucleic acid and gene therapies in the neuromuscular disorders market. Genetic disorders arise from abnormalities in an individual's DNA, either inherited or resulting from mutations. The rise in these disorders is attributed to factors such as genetic mutations, environmental influences, lifestyle changes, and advancements in diagnostic technologies. Nucleic acid and gene therapies play a crucial role in addressing genetic neuromuscular disorders by correcting or replacing defective genes to restore normal function. For example, in May 2024, according to Cure SMA, a US-based non-profit organization, approximately 9,000 to 9,500 individuals in the United States are currently living with Spinal Muscular Atrophy (SMA), with Type 2 SMA accounting for 37% of cases. The estimated incidence rate of SMA is approximately 1 in 15,000 births. As a result, the growing prevalence of genetic disorders is fueling the demand for nucleic acid and gene therapies in the neuromuscular disorders market.

Leading companies in the market are advancing gene therapy solutions to directly target the root causes of genetic neuromuscular conditions through precise gene correction or replacement. Gene therapy involves modifying or repairing genetic material within a patient's cells to address defective genes. For instance, in June 2023, Sarepta Therapeutics Inc., a US-based biotechnology company, received FDA approval for Elevidys, the first gene therapy for Duchenne Muscular Dystrophy (DMD) in ambulatory pediatric patients aged 4 to 5 years. Elevidys is administered as a single intravenous infusion, offering a simplified alternative to ongoing infusion-based therapies. This therapy delivers a gene encoding a shortened form of dystrophin, known as micro-dystrophin, which is crucial for muscle function. By enabling muscle cells to produce a functional dystrophin protein, Elevidys aims to slow or potentially reverse disease progression.

In November 2024, Novartis AG, a Switzerland-based pharmaceutical company, acquired Kate Therapeutics Inc. for $1.1 billion. This acquisition aims to strengthen Novartis' gene therapy portfolio for inherited neuromuscular diseases. By integrating Kate Therapeutics' AAV-based gene therapy platform DELIVER and its preclinical candidates for Duchenne muscular dystrophy, facioscapulohumeral dystrophy, and myotonic dystrophy type 1, Novartis is expanding its capabilities in developing targeted therapies for genetic muscle and heart diseases. Kate Therapeutics Inc. is a US-based biotechnology company specializing in adeno-associated virus (AAV)-based gene therapies for genetically defined neuromuscular conditions.

Major players in the nucleic acid and gene therapies in neuromuscular disorders market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A, Novartis AG, Eli Lilly and Company, Astellas Pharma Inc, Biogen Inc, Vertex Pharmaceuticals Inc, BioMarin Pharmaceuticals Inc, Nippon Shinyaku Co Ltd, Sarepta Therapeutics Inc, Ionis Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc, Amicus Therapeutics Inc, Arrowhead Pharmaceuticals Inc, Regenxbio Inc, UniQure N.V., Genethon S.A, Axovant Gene Therapies Inc .

North America was the largest region in the nucleic acid and gene therapies in neuromuscular disorders market in 2024. The regions covered in nucleic acid and gene therapies in neuromuscular disorders report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the nucleic acid and gene therapies in neuromuscular disorders market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nucleic acid and gene therapies in neuromuscular disorders market consist of revenue earned by entities by providing services such as genetic diagnostics, personalized therapeutics, and gene delivery. The market value includes the value of related goods sold by the service provider or included within the service offering. The nucleic acid and gene therapies in neuromuscular disorders market also include sales of oligonucleotides, gene therapy vectors, and diagnostic kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nucleic Acid And Gene Therapies In Neuromuscular Disorders Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nucleic acid and gene therapies in neuromuscular disorders market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nucleic acid and gene therapies in neuromuscular disorders ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The nucleic acid and gene therapies in neuromuscular disorders market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Disorder: Motor Neuron Diseases; Neuropathies; Neuromuscular Junction Disorders; Myopathies Including Muscular Dystrophies
  • 2) By Therapy: Adeno-Associated Viruses Gene Therapy; Postnatal Gene Therapy; Spinal Muscular Atrophy
  • 3) By Application: Hospitals; Specialty Clinics; Ambulatory Surgery Centers
  • Subsegments:
  • 1) By Motor Neuron Diseases: Amyotrophic Lateral Sclerosis (ALS); Spinal Muscular Atrophy (SMA); Primary Lateral Sclerosis (PLS)
  • 2) By Neuropathies: Charcot-Marie-Tooth Disease (CMT); Hereditary Sensory and Autonomic Neuropathy (HSAN); Peripheral Neuropathies
  • 3) By Neuromuscular Junction Disorders: Myasthenia Gravis; Lambert-Eaton Myasthenic Syndrome (LEMS)
  • 4) By Myopathies Including Muscular Dystrophies: Duchenne Muscular Dystrophy (DMD); Becker Muscular Dystrophy (BMD); Limb-Girdle Muscular Dystrophy (LGMD); Facioscapulohumeral Muscular Dystrophy (FSHD)
  • Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Bayer AG; Sanofi S.A; Novartis AG; Eli Lilly and Company; Astellas Pharma Inc; Biogen Inc; Vertex Pharmaceuticals Inc; BioMarin Pharmaceuticals Inc; Nippon Shinyaku Co Ltd; Sarepta Therapeutics Inc; Ionis Pharmaceuticals, Inc.; Ultragenyx Pharmaceutical Inc; Amicus Therapeutics Inc; Arrowhead Pharmaceuticals Inc; Regenxbio Inc; UniQure N.V.; Genethon S.A; Axovant Gene Therapies Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Characteristics

3. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Trends And Strategies

4. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Growth Rate Analysis
  • 5.4. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Total Addressable Market (TAM)

6. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Segmentation

  • 6.1. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Motor Neuron Diseases
  • Neuropathies
  • Neuromuscular Junction Disorders
  • Myopathies Including Muscular Dystrophies
  • 6.2. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Adeno-Associated Viruses Gene Therapy
  • Postnatal Gene Therapy
  • Spinal Muscular Atrophy
  • 6.3. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgery Centers
  • 6.4. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Sub-Segmentation Of Motor Neuron Diseases, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Amyotrophic Lateral Sclerosis (ALS)
  • Spinal Muscular Atrophy (SMA)
  • Primary Lateral Sclerosis (PLS)
  • 6.5. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Sub-Segmentation Of Neuropathies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Charcot-Marie-Tooth Disease (CMT)
  • Hereditary Sensory and Autonomic Neuropathy (HSAN)
  • Peripheral Neuropathies
  • 6.6. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Sub-Segmentation Of Neuromuscular Junction Disorders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Myasthenia Gravis
  • Lambert-Eaton Myasthenic Syndrome (LEMS)

7. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Regional And Country Analysis

  • 7.1. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

  • 8.1. Asia-Pacific Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

  • 9.1. China Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
  • 9.2. China Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

  • 10.1. India Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

  • 11.1. Japan Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
  • 11.2. Japan Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

  • 12.1. Australia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

  • 13.1. Indonesia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

  • 14.1. South Korea Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
  • 14.2. South Korea Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

  • 15.1. Western Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
  • 15.2. Western Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

  • 16.1. UK Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

  • 17.1. Germany Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

  • 18.1. France Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

  • 19.1. Italy Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

  • 20.1. Spain Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

  • 21.1. Eastern Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
  • 21.2. Eastern Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

  • 22.1. Russia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

  • 23.1. North America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
  • 23.2. North America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

  • 24.1. USA Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
  • 24.2. USA Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

  • 25.1. Canada Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
  • 25.2. Canada Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

  • 26.1. South America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
  • 26.2. South America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

  • 27.1. Brazil Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

  • 28.1. Middle East Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
  • 28.2. Middle East Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

  • 29.1. Africa Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
  • 29.2. Africa Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Competitive Landscape And Company Profiles

  • 30.1. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Competitive Landscape
  • 30.2. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Sanofi S.A Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Other Major And Innovative Companies

  • 31.1. Eli Lilly and Company
  • 31.2. Astellas Pharma Inc
  • 31.3. Biogen Inc
  • 31.4. Vertex Pharmaceuticals Inc
  • 31.5. BioMarin Pharmaceuticals Inc
  • 31.6. Nippon Shinyaku Co Ltd
  • 31.7. Sarepta Therapeutics Inc
  • 31.8. Ionis Pharmaceuticals, Inc.
  • 31.9. Ultragenyx Pharmaceutical Inc
  • 31.10. Amicus Therapeutics Inc
  • 31.11. Arrowhead Pharmaceuticals Inc
  • 31.12. Regenxbio Inc
  • 31.13. UniQure N.V.
  • 31.14. Genethon S.A
  • 31.15. Axovant Gene Therapies, Inc

32. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

34. Recent Developments In The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

35. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market High Potential Countries, Segments and Strategies

  • 35.1 Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제